close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Travere Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Travere Therapeutics Reports Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Report Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers ASX CSLLY TVTX
News headline image
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Reports Second Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Report Second Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Reports First Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Report First Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers ASX:CSL CSLLY TVTX
News headline image
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers ASX:CSL CSLLY TVTX
News headline image
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
News headline image
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today